Maxitrol (Neomycin Sulfate, Polymyxin B Sulfate, Dexamethasone)

Neomycin and Polymyxin B act as broad‑spectrum antibiotics; Neomycin inhibits bacterial protein synthesis, while Polymyxin B disrupts the bacterial cell membrane. Dexamethasone binds glucocorticoid receptors, suppressing inflammatory gene expression and reducing swelling, redness, and pain in the eye.

The specific dosing schedule for Maxitrol is determined by the prescribing clinician based on the severity of the infection or inflammation, patient age, and response to therapy. Patients should follow the prescriber’s instructions and the product label for proper administration.

Safety data for Maxitrol in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Healthcare providers will assess individual risk before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent antibiotic drops, Maxitrol offers the added benefit of a corticosteroid to control inflammation. Against steroid‑only drops, it provides antibacterial protection, reducing the risk of secondary infection. Choice depends on the clinical presentation and physician judgment.

Maxitrol should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and discard any product that appears discoloured or contains particles.

Maxitrol is applied as an ophthalmic suspension. The patient tilts the head back, pulls down the lower eyelid, instills the prescribed number of drops into the conjunctival sac, and closes the eye gently for a few seconds. Contact lenses should be removed before use and re‑inserted after the recommended waiting period.

Serious risks include secondary ocular infections, increased intra‑ocular pressure that may lead to glaucoma, corneal ulceration, and rare systemic effects such as adrenal suppression. Patients should report persistent pain, vision changes, or signs of infection promptly.

Maxitrol is contraindicated in patients with known hypersensitivity to any of its components, active viral eye infections (e.g., herpes simplex keratitis), and in those with uncontrolled glaucoma unless closely monitored. It should also be avoided in individuals where steroid use is contraindicated.